LSV Asset Management Sells 174,200 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

LSV Asset Management reduced its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 18.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 777,124 shares of the biopharmaceutical company's stock after selling 174,200 shares during the quarter. LSV Asset Management owned about 0.65% of Catalyst Pharmaceuticals worth $16,219,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. abrdn plc acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter worth about $10,115,000. Arrowstreet Capital Limited Partnership lifted its stake in Catalyst Pharmaceuticals by 131.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after buying an additional 396,506 shares during the period. Vanguard Group Inc. boosted its holdings in Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock worth $175,957,000 after buying an additional 390,116 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $6,887,000. Finally, JPMorgan Chase & Co. raised its position in shares of Catalyst Pharmaceuticals by 80.3% in the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock valued at $15,364,000 after acquiring an additional 327,936 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

Analyst Upgrades and Downgrades

CPRX has been the subject of a number of research analyst reports. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average target price of $32.29.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Up 1.5 %

Shares of Catalyst Pharmaceuticals stock traded up $0.33 during trading on Friday, reaching $22.52. The company's stock had a trading volume of 720,850 shares, compared to its average volume of 1,139,890. The business's 50-day moving average price is $22.60 and its 200-day moving average price is $22.07. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The firm has a market cap of $2.75 billion, a PE ratio of 19.08, a P/E/G ratio of 3.31 and a beta of 0.79.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.